Sign in
CompletedPhase 3

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Key facts

Who runs it
BioTissue Holdings, Inc
Where
Boston, Circleville, Dallas, DeLand, Delray Beach, Guntersville, Houston, Los Angeles, Mather, O'Fallon, Palmdale, Reno, Tucson, Westwood, and Whittier, United StatesSee the 16 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
106 people enrolled
Started
20 Nov 2020
Ended
24 Mar 2025
Type of study
Interventional, 2 groups
Treatments tested
  • TTAX01
  • Standard care
Record updated
1 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (28)Hide the full registry criteria

Who can take part

  • The subject has signed the informed consent form
  • The subject is male or female, at least 18 years of age inclusive at the date of Screening
  • The subject has confirmed diagnosis of Type I or Type II diabetes
  • The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot
  • The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening
  • The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule
  • The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis
  • The subject has an Ankle-Brachial Index ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg
  • The subject is under the care of a physician for the management of Diabetes Mellitus
  • The subject is willing to return for all mandatory visits as defined in the protocol
  • The subject is willing to follow the instructions of the trial Investigator

Who cannot take part

  • The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening
  • The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening
  • The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™)
  • The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine contraceptive device; or surgical sterilization of partner)
  • The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer
  • The subject's index ulcer is primarily located on the dorsal surface of the foot
  • The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure
  • The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening
  • The subject has an allergy to primary or secondary dressing materials used in this trial
  • The subject has an allergy to glycerol
  • The subject's index ulcer is over an acute Charcot deformity
  • Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection
  • The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% †
  • The subject has a contralateral major amputation of the lower extremity
  • The subject is pregnant
  • The subject is a nursing mother
  • The subject is unable to sustain off-loading as defined by the protocol

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United States
  • Cutting Edge Research, LLCCircleville, United States
  • University of Texas Southwestern Medical CenterDallas, United States
  • Midland Florida Clinical Research CenterDeLand, United States
  • Delray Physician Care CenterDelray Beach, United States
  • Lakeview Clinical ResearchGuntersville, United States
  • Advantage Foot Care of HoustonHouston, United States
  • Biolife Genetics ResearchHouston, United States
  • Clemente Clinical ResearchLos Angeles, United States
  • VA Northern California Health Care SystemMather, United States
  • Gateway Clinical Trials, LLCO'Fallon, United States
  • CureCentricPalmdale, United States
  • Reno Orthopedic ClinicReno, United States
  • Banner University Medical Center - TucsonTucson, United States
  • Curalta Foot and AnkleWestwood, United States
  • PIH HealthWhittier, United States

About the trial

What the trial wants to find out

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

The 2 groups in the trial

  • TTAX01Treatment being tested

    TTAX01 plus standard of care

    Treatment: TTAX01 and Standard care

  • ControlOther group

    Standard care alone

    Treatment: Standard care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
Record updated
1 April 2025